IP Verse

Progesterone Formulations - EP3560500

The patent EP3560500 was granted to Therapeuticsmd on Dec 22, 2021. The application was originally filed on Jun 18, 2013 under application number EP19163006A. The patent is currently recorded with a legal status of "Revoked".

EP3560500

THERAPEUTICSMD
Application Number
EP19163006A
Filing Date
Jun 18, 2013
Status
Revoked
Sep 15, 2023
Grant Date
Dec 22, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DR SCHONSep 22, 2022DR SCHONADMISSIBLE
RIECKSep 21, 2022FUCHS PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONUS2003077297
OPPOSITIONUS2011312927
OPPOSITIONUS2011312928
OPPOSITIONUS2012135074
OPPOSITIONWO2008057363
OPPOSITIONWO2013078422
OPPOSITIONWO2013192248
OPPOSITIONWO9740823
SEARCHUS2003077297
SEARCHUS2004052824
SEARCHUS2010255085
SEARCHUS2011312928
SEARCHUS6294192
SEARCHWO2013078422

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Summary of experimental results", FUCHS, (20210618), XP055969697-
OPPOSITION- B. John Cannon, Et Al., "Emulsions, Microemulsions and Lipid-based Drug Delivery Systems for Drug Solubilization and Delivery - Part II: Oral Applications", Water Insoluble Drug Formulation Second Edition, (20080101), pages 227 - 254, XP055466108-
OPPOSITION- G Monastra, S. De Grazia, L. De Luca, S. Vittorio, V. Unfer, "Vitamin D: a steroid hormone with progesterone-like activity", European Review for Medical and Pharmacological Sciences, (20180101), vol. 22, pages 2502 - 2512, XP055679171-
OPPOSITION- John Cannon B; Et Al, "Emulsions, Microemulsions and Lipid-based Drug Delivery Systems for Drug Solubilization and Delivery - Part II: Oral Applications", John Cannon B; Et Al, LIU, RONG, Water Insoluble Drug Formulation Second Edition, CRC PRESS, (20000000), vol. 11, pages 227 - 231, XP055466108-
OPPOSITION- N.V. GOLETIANI et al., "Progesterone: Review of Safety for Clinical Studies", Experimental and Clinical Psychopharmacology, (20070000), vol. 15, no. 5, pages 427 - 444, XP055971675-
OPPOSITION- Summary of Product Characteristics of Prometrium, (20090600), URL: https://www.accessdata.fda.gov/drugsatfda_docs/la- bel/2009/0 19781 s0 13lbl. pdf-
OPPOSITION- The North American Menopause Society, "The 2012 Hormone Therapy Position Statement of The North American Meno- pause Society", Menopause, (20120301), vol. 19, no. 3, pages 257 - 271, XP055907213-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents